2008 International Meeting: The Molecular Biology of Hepatitis B Viruses

2008 年国际会议：乙型肝炎病毒的分子生物学

• 批准号: 7484813
• 负责人: Stefan Frank Wieland
• 金额: $ 1.5万
• 依托单位: HEPATITIS B FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7484813
• 关键词: Address; Advocate; Antiviral Agents; Basic Science; California; Cellular biology; Cessation of life; Cirrhosis; Educational workshop; Foundations; Funding; Hepatitis B; Hepatitis B Virus; Hepatitis D; Hepatitis Delta Virus; Immune response; Immunity; Individual; Infection; International; Liver Failure; Metabolism; Minority; Molecular Biology; Numbers; Oral; Primary carcinoma of the liver cells; Public Health; RNA; Rate; Research Personnel; Schedule; Scientist; Series; Structure; Therapeutic; Time; Underrepresented Minority; United States National Institutes of Health; Universities; Vaccinated; Vaccines; Viral; Virus; Virus Diseases; cost; posters; prophylactic; trafficking; virus host interaction

DESCRIPTION (provided by applicant): This application is intended to apply for funding support for the expenses necessary to host the 2008 International Meeting: The Molecular Biology of Hepatitis B Viruses (HBV Meeting), scheduled to be held from August 17 through 21, 2008 at the University of California San Diego campus in La Jolla, CA. This is the next scheduled meeting in an annual series that has been held continuously since 1985. This meeting represents the only meeting that brings together basic scientists in the field of hepatitis B virus (HBV) and hepatitis D (delta) virus (HDV) from around the world. HBV continues to be a major global and US public health problem. Despite the availability of prophylactic vaccines, many new infections occur worldwide, partly because of the lack of an immune response in some (=10%) of the vaccinated people, but mostly because of underutilization of the vaccine, due to cost and other issues. Moreover, for the more than 350 million people already chronically infected with HBV (approximately 15 million of whom are co-infected with HDV), the vaccine is of no therapeutic value. As a result, between 0.5 to 1 million people die of HBV/HDV every year worldwide. It is therefore imperative that basic research and the scientific exchange among those studying HBV/HDV continues and the annual HBV meeting represents the venue at which this can occur. The 2008 meeting will continue in this tradition by enhancing the interaction and dialog with ten oral scientific sessions, two poster sessions as well as less structured "networking" time. A special focus of this meeting will be on viral entry, trafficking and host-virus interactions, with a special emphasis on cell biology, RNA metabolism, and antiviral immunity. This will be facilitated by two immunity related keynote addresses accompanied by a special workshop focused on viral entry and trafficking. As always, great effort has been made to minimize the cost of the meeting. Furthermore, the Hepatitis B Foundation has made a strong commitment to advocate and advance this meeting since 2005, in terms of providing consistent support responsible for meeting organization and promotion. Promotional targets have included universities with large numbers of underrepresented minorities. In order to allow the participation of junior and minority investigators, support from the National Institutes of Health (NIH) to help defray the meeting costs of junior scientists is requested. Limited support for meeting materials and organizational functions is also needed. The 2008 International Meeting: The Molecular Biology of Hepatitis B Viruses is the next scheduled meeting in an annual series that has been held continuously since 1985. The HBV meeting is a critical and internationally renowned platform for continued exchange of information in basic research on HBV and HDV infections in that it is the only definitive meeting of its kind, bringing together basic scientists in the field of hepatitis B virus (HBV) and hepatitis D virus (HDV) from around the world. HBV continues to be a major global and US public health problem with more than 350 millions individuals chronically infected worldwide and with an annual rate of up to one million deaths due to HBV and HBV/HDV-induced liver failure, cirrhosis, and hepatocellular carcinoma.

描述（由申请人提供）： 本申请旨在申请资助举办2008年国际会议所需的费用：B肝炎病毒的分子生物学（HBV会议），定于2008年8月17日至21日在加利福尼亚州拉霍亚的加州大学圣地亚哥分校举行。这是自1985年以来连续举行的年度系列会议中的下一次排定的会议。本次会议是唯一一次汇集了来自世界各地的B型肝炎病毒（HBV）和丁型肝炎病毒（HDV）领域的基础科学家的会议。HBV仍然是一个主要的全球和美国公共卫生问题。尽管预防性疫苗的可用性，许多新的感染发生在世界范围内，部分原因是一些（=10%）接种疫苗的人缺乏免疫应答，但主要是因为疫苗利用不足，由于成本和其他问题。此外，对于已经慢性感染HBV的3.5亿多人（其中约1500万人合并感染HDV），疫苗没有治疗价值。因此，全世界每年有50万至100万人死于HBV/HDV。因此，基础研究和HBV/HDV研究人员之间的科学交流必须继续下去，年度HBV会议是可能发生这种情况的场所。2008年的会议将继续这一传统，通过加强互动和对话与十个口头科学会议，两个海报会议以及结构较少的“网络”时间。本次会议的一个特别重点将是病毒进入，运输和宿主病毒的相互作用，特别强调细胞生物学，RNA代谢和抗病毒免疫。这将通过两个与免疫有关的主旨演讲以及一个侧重于病毒进入和贩运的特别讲习班来促进。同以往一样，已作出巨大努力尽量减少会议费用。此外，自2005年以来，B型肝炎基金会一直坚定地致力于宣传和推动这次会议，为会议的组织和宣传提供持续的支持。宣传对象包括少数民族人数众多、代表性不足的大学。为了让初级和少数民族研究人员参与，请美国国立卫生研究院（NIH）提供支持，帮助支付初级科学家的会议费用。还需要对会议材料和组织职能提供有限的支助。2008年国际会议：B型肝炎病毒的分子生物学是自1985年以来连续举行的年度系列会议中的下一个预定会议。HBV会议是HBV和HDV感染基础研究持续信息交流的重要和国际知名平台，因为它是同类会议中唯一的权威会议，汇集了来自世界各地的B病毒（HBV）和丁型肝炎病毒（HDV）领域的基础科学家。HBV仍然是全球和美国的一个主要公共卫生问题，全球有超过3.5亿人慢性感染，每年有多达100万人死于HBV和HBV/HDV诱导的肝衰竭、肝硬化和肝细胞癌。